Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics

Cavaletti G, et al.

Lancet Oncol. 2011 November;12(12):1151-1161

 

Abstract

Development of advanced and high-throughput methods to study variability in human genes means we can now use pharmacogenomic analysis not only to predict response to treatment but also to assess the toxic action of drugs on normal cells (so-called toxicogenomics). This technological progress could enable us to identify individuals at high and low risk for a given side-effect. Pharmacogenomics could be very useful for stratification of cancer patients at risk of developing chemotherapy-induced peripheral neurotoxicity, one of the most severe and potentially permanent non-haematological side-effects of modern chemotherapeutic agents. However, study data reported so far are inconsistent, which suggests that methodological improvement is needed in clinical trials to obtain reliable results in this clinically relevant area.

Copyright © 2011 Elsevier Ltd. All rights reserved.


E-Alert

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre


Search this site

Search form